Table 2.
Univariate and multivariate Cox regression models in the propensity score-matched cohort
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Group | ||||
| PCT + RT vs. PCT + CCRT | 0.67 (0.46–0.97) | 0.036 | 0.59 (0.39–0.88) | 0.009 |
| Age (years) | ||||
| < 45 vs. ≥ 45 | 1.18 (0.81–1.72) | 0.389 | ||
| Sex | ||||
| Male vs. Female | 0.53 (0.28–1.00) | 0.054 | 0.50 (0.27–0.94) | 0.033 |
| Diagnosis period | ||||
| 2000–2005 vs. 2006–2011 | 0.52 (0.30–0.92) | 0.025 | ||
| 2000–2005 vs. 2012–2017 | 0.46 (0.27–0.77) | 0.003 | ||
| Pathology | ||||
| I-II vs. III | 0.78 (0.58–1.04) | 0.093 | ||
| Tumor category | ||||
| T1-2 vs. T3-4 | 1.06 (0.61–1.83) | 0.834 | ||
| Node category | ||||
| N0-1 vs. N2-3 | 1.10 (0.71–1.71) | 0.670 | ||
| Bone metastasis | ||||
| Absent vs. Single | 0.66 (0.39–1.11) | 0.117 | ||
| Absent vs. Multiple | 1.77 (0.87–2.12) | 0.177 | ||
| Liver metastasis | ||||
| Absent vs. Single | 0.83 (0.40–1.71) | 0.606 | 1.06 (0.51–2.22) | 0.871 |
| Absent vs. Multiple | 2.32 (1.38–3.88) | 0.001 | 1.95 (1.13–3.35) | 0.016 |
| Lung metastasis | ||||
| Absent vs. Single | 0.79 (0.38–1.62) | 0.514 | ||
| Absent vs. Multiple | 1.32 (0.74–2.37) | 0.346 | ||
| Distant nodal metastasis | ||||
| Absent vs. Present | 1.53 (0.92–2.55) | 0.100 | ||
| No. of metastatic organs | ||||
| Single organ vs. Multiple organs | 1.62 (0.98–2.66) | 0.059 | ||
| Metastatic situation | ||||
| Organ metastasis without LN involvement vs. Organ metastasis with LN involvement | 1.26 (0.94–1.69) | 0.116 | ||
| No. of metastatic lesions | ||||
| Oligo vs. Multiple | 2.18 (1.42–3.34) | < 0.001 | 1.97 (1.23–3.16) | 0.005 |
| PCT regimen | ||||
| PF vs. TP | 1.21 (0.77–1.91) | 0.415 | ||
| PF vs. TPF | 0.65 (0.40–1.05) | 0.077 | ||
| No. of PCT cycles | ||||
| 1–3 vs. 4–6 | 0.61 (0.40–0.92) | 0.020 | 0.49 (0.31–0.77) | 0.002 |
| 1–3 vs. > 6 | 0.47 (0.18–1.22) | 0.120 | 0.27 (0.09–0.77) | 0.014 |
| Response to PCT | ||||
| CR/PR vs. SD | 1.19 (0.93–1.53) | 0.159 | ||
| KPS before RT | ||||
| 90 vs. 70–80 | 1.30 (0.69–2.42) | 0.417 | ||
| Technique of RT | ||||
| Conventional RT vs. IMRT | 0.74 (0.49–1.13) | 0.162 | ||
| Local treatment of metastatic sites | ||||
| No vs. Yes | 0.65 (0.44–0.98) | 0.040 | 0.69 (0.45–1.05) | 0.082 |
PCT palliative chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy, HR hazard ratio, CI confidence interval, No. number, LN lymph node, PF cisplatin plus 5-fluorouracil, TP cisplatin plus docetaxel, TPF cisplatin plus docetaxel plus 5-fluorouracil, CR complete response, PR partial response, SD stable disease, KPS Karnofsky performance score, IMRT intensity-modulated radiotherapy